Mechanical Circulatory Support in Patients With COVID-19 Presenting With Myocardial Infarction

Raviteja R. Guddeti, Cristina Sanina, Rajiv Jauhar, Timothy D. Henry, Payam Dehghani, Ross Garberich, Christian W. Schmidt, Keshav R. Nayak, Jay S. Shavadia, Akshay Bagai, Chadi Alraies, Aditya Mehra, Rodrigo Bagur, Cindy Grines, Avneet Singh, Rajan A.G. Patel, Wah Wah Htun, Nima Ghasemzadeh, Laura Davidson, Deepak AcharyaAmeer Kabour, Abdul Moiz Hafiz, Shy Amlani, Hal S. Wasserman, Timothy Smith, Navin K. Kapur, Santiago Garcia*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


ST-segment elevation myocardial infarction (STEMI) complicating COVID-19 is associated with an increased risk of cardiogenic shock and mortality. However, little is known about the frequency of use and clinical impact of mechanical circulatory support (MCS) in these patients. We sought to define patterns of MCS utilization, patient characteristics, and outcomes in patients with COVID-19 with STEMI. The NACMI (North American COVID-19 Myocardial Infarction) is an ongoing prospective, observational registry of patients with COVID-19 positive (COVID-19+) with STEMI with a contemporary control group of persons under investigation who subsequently tested negative for COVID-19 (COVID-19−). We compared the baseline characteristics and in-hospital outcomes of COVID-19+ and patients with COVID-19− according to the use of MCS. The primary outcome was a composite of in-hospital mortality, stroke, recurrent MI, and repeat unplanned revascularization. A total of 1,379 patients (586 COVID-19+ and 793 COVID-19−) enrolled in the NACMI registry between January 2020 and November 2021 were included in this analysis; overall, MCS use was 12.3% (12.1% [n = 71] COVID-19+/MCS positive [MCS+] vs 12.4% [n = 98] COVID-19−/MCS+). Baseline characteristics were similar between the 2 groups. The use of percutaneous coronary intervention was similar between the groups (84% vs 78%; p = 0.404). Intra-aortic balloon pump was the most frequently used MCS device in both groups (53% in COVID-19+/MCS+ and 75% in COVID-19−/MCS+). The primary outcome was significantly higher in COVID-19+/MCS+ patients (60% vs 30%; p = 0.001) because of very high in-hospital mortality (59% vs 28%; p = 0.001). In conclusion, patients with COVID-19+ with STEMI requiring MCS have very high in-hospital mortality, likely related to the significantly higher pulmonary involvement compared with patients with COVID-19− with STEMI requiring MCS.

Original languageEnglish (US)
Pages (from-to)76-83
Number of pages8
JournalAmerican Journal of Cardiology
StatePublished - Jan 15 2023

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Mechanical Circulatory Support in Patients With COVID-19 Presenting With Myocardial Infarction'. Together they form a unique fingerprint.

Cite this